Chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria, presents as hives that persist daily or almost daily for six weeks or longer without an obvious known stimulus. Drug treatment is largely dominated by antihistamines. However, one biologic, Novartis / Roche’s Xolair, is approved for chronic idiopathic urticaria; clinical guidelines recommend it as a third-line treatment. Xolair’s dominance demonstrates that opportunity remains in the CSU market for other biologics in development. In addition, montelukast is a key drug in the CSU market and a preferred combination agent, consistent with the recommended use of leukotriene receptor antagonists as add-on treatment in the current urticaria treatment guidelines.
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CSU patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CSU patients?
- How has Xolair been integrated into the treatment algorithm, and what is its source of business?
- What percentage of CSU patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of CSU patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Urticaria - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis - Chronic Spontaneous Urticaria (US)
Author(s): Yingdee Unhavaithaya
Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis.
Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials progression. He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing opportunities. Yingdee received his Ph.D. in cell biology from the University of Massachusetts Medical School, and a B.S. in biology from the University of Pittsburgh at Greensburg.